Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Epigenetic gene silencing in cancer
Benjamin Tycko
Benjamin Tycko
Published February 15, 2000
Citation Information: J Clin Invest. 2000;105(4):401-407. https://doi.org/10.1172/JCI9462.
View: Text | PDF
Perspective

Epigenetic gene silencing in cancer

  • Text
  • PDF
Abstract

Authors

Benjamin Tycko

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Hypothetical pathways for de novo methylation of gene promoters in cance...
Hypothetical pathways for de novo methylation of gene promoters in cancer precursor cells. (a) Primary silencing by loss of activating transcription factors, followed by secondary de novo methylation. (b) Primary silencing by overexpression of transcriptional repressors, followed by secondary de novo methylation. (c) Primary de novo methylation by hyperexpressed DNA methyltransferase, without loss of transcription factors. (d) Interallelic transfer of DNA methylation at a locus with preexisting allele-specific hypermethylation (either parental imprinting or “first-hit” de novo methylation). Methylated DNA is shown in red. The gene promoter is in blue, and changes in chromatin configuration are indicated by a change in shape. Activating transcription factors are in gray, and repressor proteins are in yellow. The red arrows are methylated repetitive elements, and the black arrows indicate gene transcription. In a–c, DNA methylation is shown as spreading from preexisting methylated sequences within the repetitive elements.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts